New antiviral agents for the treatment of hepatitis C: ABT-450

Andres F. Carrion, Julio Gutierrez, Paul Martin

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Introduction: Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88-100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging. Areas covered: Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented. Expert opinion: Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.

Original languageEnglish (US)
Pages (from-to)711-716
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Issue number5
StatePublished - Apr 2014


  • ABT-450
  • Antiviral agents
  • Hepatitis C
  • Protease inhibitors
  • Sustained virological response

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'New antiviral agents for the treatment of hepatitis C: ABT-450'. Together they form a unique fingerprint.

Cite this